Atahan, L. Et Al. 2010. Zoledronic acid concurrent with either high-or reduced-dose palliative radiotherapy in the management of the breast cancer patients with bone metastases: A phase IV randomized clinical study. Supportive Care in Cancer , vol.18, no.6 , 691-698.

Atahan, L., Yildiz, F., Cengiz, M., Kaplan, B., Özkan, M., Yazici, G., ... Gündoǧ, M.(2010). Zoledronic acid concurrent with either high-or reduced-dose palliative radiotherapy in the management of the breast cancer patients with bone metastases: A phase IV randomized clinical study. Supportive Care in Cancer , vol.18, no.6, 691-698.

Atahan, Lale Et Al. "Zoledronic acid concurrent with either high-or reduced-dose palliative radiotherapy in the management of the breast cancer patients with bone metastases: A phase IV randomized clinical study," Supportive Care in Cancer , vol.18, no.6, 691-698, 2010

Atahan, Lale Et Al. "Zoledronic acid concurrent with either high-or reduced-dose palliative radiotherapy in the management of the breast cancer patients with bone metastases: A phase IV randomized clinical study." Supportive Care in Cancer , vol.18, no.6, pp.691-698, 2010

Atahan, L. Et Al. (2010) . "Zoledronic acid concurrent with either high-or reduced-dose palliative radiotherapy in the management of the breast cancer patients with bone metastases: A phase IV randomized clinical study." Supportive Care in Cancer , vol.18, no.6, pp.691-698.

@article{article, author={Lale Atahan Et Al. }, title={Zoledronic acid concurrent with either high-or reduced-dose palliative radiotherapy in the management of the breast cancer patients with bone metastases: A phase IV randomized clinical study}, journal={Supportive Care in Cancer}, year=2010, pages={691-698} }